KopranKOPRAN 
3.53%24h
Kopran (KOPRAN) Stock Overview
Kopran Limited, an integrated pharmaceutical company, manufactures and sells active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as topical preparations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti-helmentics, anti-histamine, anti-acne, anti-infective, urological, anti-thrombotic, antidiabetic, pain management, gastroenterology, and cardiovascular. In addition, the company provides drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is headquartered in Mumbai, India.
KOPRAN Stock Information
Kopran (KOPRAN) Price Chart
Kopran Overview: Key Details and Summary
Stock data | 2023 | Change |
|---|---|---|
| Price | $4.12 | N/A |
| Market Cap | $198.83M | N/A |
| Shares Outstanding | 48.21M | 8.80% |
| Employees | 902.00 | N/A |
| Shareholder Equity | 4.39B | 3.07% |
Valuation | 2023 | Change |
|---|---|---|
| P/E Ratio | 0.73 | N/A |
| P/S Ratio | 3.04 | N/A |
| P/B Ratio | 0.05 | N/A |
Growth | 2023 | Change |
|---|---|---|
| Return on Equity | 0.0007 | N/A |
Earnings | 2023 | Change |
|---|---|---|
| Revenue | $65.35M | N/A |
| Earnings | $3.25M | N/A |
| EPS | 5.65 | N/A |
| Earnings Yield | 1.37 | N/A |
| Gross Margin | 0.3177 | N/A |
| Operating Margin | 0.0826 | N/A |
| Net income margin | 0.0497 | N/A |
Financial Strength | 2023 | Change |
|---|---|---|
| Total Assets | $77.45M | N/A |
| Total Debt | $8.97M | N/A |
| Cash on Hand | $1.51M | N/A |
| Debt to Equity | 0.0057 | 10.54% |
| Cash to Debt | 0.1681 | -79.03% |
| Current Ratio | $2.25 | -17.61% |
